Literature DB >> 24056771

Cellular immune correlates of protection against symptomatic pandemic influenza.

Saranya Sridhar1, Shaima Begom, Alison Bermingham, Katja Hoschler, Walt Adamson, William Carman, Thomas Bean, Wendy Barclay, Jonathan J Deeks, Ajit Lalvani.   

Abstract

The role of T cells in mediating heterosubtypic protection against natural influenza illness in humans is uncertain. The 2009 H1N1 pandemic (pH1N1) provided a unique natural experiment to determine whether crossreactive cellular immunity limits symptomatic illness in antibody-naive individuals. We followed 342 healthy adults through the UK pandemic waves and correlated the responses of pre-existing T cells to the pH1N1 virus and conserved core protein epitopes with clinical outcomes after incident pH1N1 infection. Higher frequencies of pre-existing T cells to conserved CD8 epitopes were found in individuals who developed less severe illness, with total symptom score having the strongest inverse correlation with the frequency of interferon-γ (IFN-γ)(+) interleukin-2 (IL-2)(-) CD8(+) T cells (r = -0.6, P = 0.004). Within this functional CD8(+)IFN-γ(+)IL-2(-) population, cells with the CD45RA(+) chemokine (C-C) receptor 7 (CCR7)(-) phenotype inversely correlated with symptom score and had lung-homing and cytotoxic potential. In the absence of crossreactive neutralizing antibodies, CD8(+) T cells specific to conserved viral epitopes correlated with crossprotection against symptomatic influenza. This protective immune correlate could guide universal influenza vaccine development.

Entities:  

Mesh:

Year:  2013        PMID: 24056771     DOI: 10.1038/nm.3350

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  57 in total

1.  Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans.

Authors:  Tom M Wilkinson; Chris K F Li; Cecilia S C Chui; Arthur K Y Huang; Molly Perkins; Julia C Liebner; Rob Lambkin-Williams; Anthony Gilbert; John Oxford; Ben Nicholas; Karl J Staples; Tao Dong; Daniel C Douek; Andrew J McMichael; Xiao-Ning Xu
Journal:  Nat Med       Date:  2012-01-29       Impact factor: 53.440

2.  Induction of partial immunity to influenza by a neuraminidase-specific vaccine.

Authors:  R B Couch; J A Kasel; J L Gerin; J L Schulman; E D Kilbourne
Journal:  J Infect Dis       Date:  1974-04       Impact factor: 5.226

3.  Marked differences in CCR5 expression and activation levels in two South African populations.

Authors:  Anabela C P Picton; Sharon Shalekoff; Maria Paximadis; Caroline T Tiemessen
Journal:  Immunology       Date:  2012-08       Impact factor: 7.397

4.  Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses.

Authors:  Andres G Grandea; Ole A Olsen; Thomas C Cox; Mark Renshaw; Philip W Hammond; Po-Ying Chan-Hui; Jennifer L Mitcham; Witold Cieplak; Shaun M Stewart; Michael L Grantham; Andrew Pekosz; Maki Kiso; Kyoko Shinya; Masato Hatta; Yoshihiro Kawaoka; Matthew Moyle
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-01       Impact factor: 11.205

5.  Diagnosis of influenza in the community: relationship of clinical diagnosis to confirmed virological, serologic, or molecular detection of influenza.

Authors:  M Zambon; J Hays; A Webster; R Newman; O Keene
Journal:  Arch Intern Med       Date:  2001-09-24

6.  Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice.

Authors:  J H C M Kreijtz; R Bodewes; G van Amerongen; T Kuiken; R A M Fouchier; A D M E Osterhaus; G F Rimmelzwaan
Journal:  Vaccine       Date:  2006-09-07       Impact factor: 3.641

7.  Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus.

Authors:  J H C M Kreijtz; G de Mutsert; C A van Baalen; R A M Fouchier; A D M E Osterhaus; G F Rimmelzwaan
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

8.  Yearly influenza vaccinations: a double-edged sword?

Authors:  Rogier Bodewes; Joost H C M Kreijtz; Guus F Rimmelzwaan
Journal:  Lancet Infect Dis       Date:  2009-10-30       Impact factor: 25.071

9.  Rapid effector function in CD8+ memory T cells.

Authors:  A Lalvani; R Brookes; S Hambleton; W J Britton; A V Hill; A J McMichael
Journal:  J Exp Med       Date:  1997-09-15       Impact factor: 14.307

Review 10.  Closure of schools during an influenza pandemic.

Authors:  Simon Cauchemez; Neil M Ferguson; Claude Wachtel; Anders Tegnell; Guillaume Saour; Ben Duncan; Angus Nicoll
Journal:  Lancet Infect Dis       Date:  2009-08       Impact factor: 25.071

View more
  394 in total

1.  Report on the second WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Geneva, Switzerland, 5-7 May 2014.

Authors:  Nancy J Cox; Julian Hickling; Rebecca Jones; Guus F Rimmelzwaan; Linda C Lambert; John Boslego; Larisa Rudenko; Leena Yeolekar; James S Robertson; Joachim Hombach; Justin R Ortiz
Journal:  Vaccine       Date:  2015-10-23       Impact factor: 3.641

Review 2.  Sizing up the key determinants of the CD8(+) T cell response.

Authors:  David C Tscharke; Nathan P Croft; Peter C Doherty; Nicole L La Gruta
Journal:  Nat Rev Immunol       Date:  2015-10-09       Impact factor: 53.106

3.  Epitope specific T-cell responses against influenza A in a healthy population.

Authors:  Miloje Savic; Jennifer L Dembinski; Yohan Kim; Gro Tunheim; Rebecca J Cox; Fredrik Oftung; Bjoern Peters; Siri Mjaaland
Journal:  Immunology       Date:  2015-12-08       Impact factor: 7.397

Review 4.  Progress on adenovirus-vectored universal influenza vaccines.

Authors:  Kui Xiang; Guan Ying; Zhou Yan; Yan Shanshan; Zhang Lei; Li Hongjun; Sun Maosheng
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  Positive Selection in CD8+ T-Cell Epitopes of Influenza Virus Nucleoprotein Revealed by a Comparative Analysis of Human and Swine Viral Lineages.

Authors:  Heather M Machkovech; Trevor Bedford; Marc A Suchard; Jesse D Bloom
Journal:  J Virol       Date:  2015-08-26       Impact factor: 5.103

Review 6.  Influenza-induced lung Trm: not all memories last forever.

Authors:  Natalija Van Braeckel-Budimir; John T Harty
Journal:  Immunol Cell Biol       Date:  2017-04-13       Impact factor: 5.126

7.  Characterization of antibody and memory T-cell response in H7N9 survivors: a cross-sectional analysis.

Authors:  M-J Ma; X-X Wang; M-N Wu; X-J Wang; C-J Bao; H-J Zhang; Y Yang; K Xu; G-L Wang; M Zhao; W Cheng; W-J Chen; W-H Zhang; L-Q Fang; W J Liu; E-F Chen; W-C Cao
Journal:  Clin Microbiol Infect       Date:  2019-06-20       Impact factor: 8.067

8.  Calcium phosphate nanoparticle (CaPNP) for dose-sparing of inactivated whole virus pandemic influenza A (H1N1) 2009 vaccine in mice.

Authors:  Tülin Morçӧl; Brett L Hurst; E Bart Tarbet
Journal:  Vaccine       Date:  2017-07-14       Impact factor: 3.641

9.  Influenza B virus-specific CD8+ T-lymphocytes strongly cross-react with viruses of the opposing influenza B lineage.

Authors:  Carolien E van de Sandt; YingYing Dou; Stella E Vogelzang-van Trierum; Kim B Westgeest; Mark R Pronk; Albert D M E Osterhaus; Ron A M Fouchier; Guus F Rimmelzwaan; Marine L B Hillaire
Journal:  J Gen Virol       Date:  2015-04-21       Impact factor: 3.891

Review 10.  Influenza vaccines: challenges and solutions.

Authors:  Katherine Houser; Kanta Subbarao
Journal:  Cell Host Microbe       Date:  2015-03-11       Impact factor: 21.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.